Special Delivery $19.043M Market Capitalization Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of…
blood brain barrier
Nice Mice Considering the amount of junk food I have eaten in the past week, I figured now is as good a time as any to talk about…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain….
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an…
Bioasis Technologies (BTI.V) hired Shadow Lake Group, and affiliate, SLG Europe BV, as a business development adviser earlier this week, according to a press release. This one’s a…
Bioasis Technologies (BTI.V) announces today that the Japanese Patent Office (JPO) has issued Japanese Patent No.2019-189551 Notice of Allowance for the Company’s xB3™-IDS fusion proteins. “We are excited about…
Bioasis Technologies (BTI.V) announced they are entering into a research collaboration with Oxyrane UK. As Equity Guru previously reported, Bioasis is developing the xB³ platform, which aims penetrate the…